Data as of . Holdings from the fund’s latest public SEC N-PORT filing; overlap and active share computed by ETFIQ against the IVV and QQQM books; returns from Tiingo end-of-day prices with distributions reinvested.
FMED · Fidelity Disruptive Medicine ETF
Fidelity · Themes desk
Open the live card on ETFIQBy weight, 25% of FMED's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 97%. The top ten holdings are 32% of the fund across 68 positions, as filed for May 31, 2026. Over the year to Sep 4, 2026 the fund returned +28.5% with distributions reinvested against +20.0% for the S&P 500, so a holder was ahead by 8.6 pts.
| Theme (ETFIQ, editorial) | Broad innovation and megatrends |
|---|---|
| Launched | Jun 12, 2023 |
| Already in the S&P 500, by weight (ETFIQ) | 25.4% |
| Active share vs the S&P 500 (ETFIQ) | 97.1% |
| Already in the Nasdaq-100, by weight (ETFIQ) | 8.7% |
| Active share vs the Nasdaq-100 (ETFIQ) | 98.9% |
| Top ten holdings weight | 31.5% |
| Holdings | 68 |
| Net assets (latest filing) | $41M |
| Holdings as of (SEC N-PORT) | May 31, 2026 |
| Top holdings | UCB SA 4.8%, LIFESTANCE HEALTH GROUP INC 4.3%, DANAHER CORP 3.4%, 10X GENOMICS INC 3.1%, INTUITIVE SURGICAL INC 2.9%, COGENT BIOSCIENCES INC 2.9%, ALNYLAM PHARMACEUTICALS INC 2.8%, ARGENX SE 2.8%, LEGEND BIOTECH CORP 2.3%, UNITEDHEALTH GROUP INC 2.3% |
| 3 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +29.4% / +4.7% / +24.7 pts / +27.3 pts |
| 6 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +26.5% / +15.2% / +11.4 pts / +6.4 pts |
| 1 year: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +28.5% / +20.0% / +8.6 pts / +2.9 pts |
| 3 years: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +34.4% / +78.0% / −43.5 pts / −59.0 pts |
| since launch: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +26.3% / +85.0% / −58.7 pts / −76.9 pts |
| Below its all-time high (ETFIQ) | −3.4% |
| Expense ratio (prospectus XBRL) | 0.50% |
| Fee for the part that differs from the S&P 500, active expense ratio (ETFIQ) | 0.51% |
| Closest funds by holdings overlap | HTEC 22%, EKG 22%, GNOM 19%, HEAL 16%, HELX 15% |
Questions people ask
- How much of FMED is already in the S&P 500?
- By its holdings filed for May 31, 2026, 25% of FMED by weight is stocks the S&P 500 already holds. Its active share against the index is 97%, so that share is the part doing something different.
- What does FMED hold?
- 68 positions as filed for May 31, 2026, with the top ten at 32% of the fund. The largest are UCB SA at 4.8%, LIFESTANCE HEALTH GROUP INC at 4.3%, DANAHER CORP at 3.4%.
- Has FMED beaten the S&P 500?
- Over the year to Sep 4, 2026 FMED returned +28.5% with distributions reinvested, against +20.0% for the S&P 500, so it finished ahead of the index by 8.6 points.
- What does FMED cost?
- The prospectus expense ratio is 0.50% a year. Because 97% of the fund differs from the S&P 500, the fee on that differing part works out at 0.51%.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Funds near this one
Put this on your own page
The difference bar for FMED, redrawn every trading night. Free to use with the credit link; paste these two lines into any page or newsletter.
<a href="https://etfiq.com/funds/FMED.html"><img src="https://etfiq.com/embed/themes/FMED.svg" alt="FMED difference bar, ETFIQ" width="640"></a>
<p><a href="https://etfiq.com/funds/FMED.html">FMED difference bar, updated daily by ETFIQ</a></p>Cite this page. ETFIQ, FMED on the themes desk, data as of Sep 4, 2026. https://etfiq.com/funds/FMED.html Free to use with attribution; the underlying files are at Open data.
ETFIQ is an independent publisher of exchange-traded fund data. It is not a fund issuer, broker-dealer or investment adviser, and it makes no recommendations; sort orders and figures are stated arithmetic on published data. Standards · How to read this desk